

CURRICULUM VITAE

NAME	RUOLO
Claudio Sorio	Professore Associato

Nato a Verona il 21 settembre, 1962. Nazionalità: Italiana

EDUCAZIONE

ISTITUZIONE E LUOGO	TITOLO	ANNI	CAMPO
Università di Verona	Medicina e chirurgia	1982-1988	Medicina
Università di Verona	Dottorato di ricerca	1990-1994	Biologia e patologia molecolare e cellulare
Università di Verona	Specializzazione	1994-1998	Anatomia Patologica

Attività

1989-1990:	Sottotenente medico responsabile del servizio sanitario del presidio militare di Verona
1992-1995:	Ricercatore a contratto: Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, U.S.A.
1991-1998:	Ricercatore in visita (2 mesi) all'EMBL, Heidelberg (Dr. Sara Courtneidge lab, 1991) e Ulm University (Prof. Thomas Gress, 16-07-2008 fino a 26-08-2008)
1998-present	Ricercatore Universitario a TI, diversi soggiorni presso Diamond Light Source (Didcot, UK), National Center for Cancer Care & Research (NCCCR) Doha, Qatar, University of Minnesota, (USA).
2012-present	Responsabile designato dei laboratori di "Biomarcatori", "Ricerca traslazionale in Fibrosi Cistica" presso il Dipartimento di Medicina (http://www.cfcverona.it/LabRicTras.html)
2014	Nominato Faculty Member (Visiting Professor) al Department of Biochemistry and Cell Biology, University of Minnesota (U.S.A.)
2017	ASN I fascia nei SC 06A2 (Patologia generale e Patologia clinica) e 06N1 (Scienze delle professioni sanitarie e delle tecnologie mediche applicate)
2018	Professore Associato (SC 06/A2, SSD MED04)
2019	Visiting professor, Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam (NL)

Campo di ricerca

Biomarcatori in oncologia e in fibrosi cistica. Caratterizzazione biochimica e funzionale del gene oncosoppressore PTPRG e del prodotto del gene CFTR.

Pubblicazioni

Autore di 115 pubblicazioni presenti nella banca dati Pubmed. Impact factor (riferito all'anno di pubblicazione): 567, media IF: 5,2. Citazioni: 3210, h index 27 (Scopus) a agosto 2024

1: Berton G, Sorio C, Laudanna C, Menegazzi M, Carcereri De Prati A, Suzuki H. Activation of human monocyte-derived macrophages by interferon gamma is accompanied by increase of poly(ADP-ribose) polymerase activity. *Biochim Biophys Acta*. 1991 Jan 10;1091(1):101-9. doi: 10.1016/0167-4889(91)90228-p. PMID:1899803.
IF 2002: 3,016

2: Poli G, Sorio C, Berton G. Protein myristoylation in human mononuclear phagocytes: modulation by interferon-gamma and tumor necrosis factor-alpha. *J. Cell Sci*. 1991 Dec;100 (Pt 4):833-40. doi: 10.1242/jcs.100.4.833. PMID:1726103.
IF 2002: 6,954

3: Berton G, Laudanna C, Sorio C, Rossi F. Generation of signals activating neutrophil functions by leukocyte integrins: LFA-1 and gp150/95, but not CR3, are able to stimulate the respiratory burst of human neutrophils. *J Cell Biol*. 1992 Feb;116(4):1007-17. doi: 10.1083/jcb.116.4.1007. PMID: 1346398; PMCID:PMC2289342.
IF 2002: 12,522

4: Amezcua MA, Bazzoni F, Sorio C, Rossi F, Cassatella MA. Evidence for the involvement of distinct signal transduction pathways in the regulation of constitutive and interferon gamma-dependent gene expression of NADPH

oxidase components (gp91-phox, p47-phox, and p22-phox) and high-affinity receptor for IgG (Fc gamma R-I) in human polymorphonuclear leukocytes. *Blood*. 1992 Feb 1;79(3):735-44. PMID: 1531037.

IF 2002: 9,631

5: Cassatella MA, Trinchieri G, Hassan NF, Hartman L, Sorio C, Berton G. Induction of differentiation of the human myeloid cell line, ML3, by tumour necrosis factor and interferon-gamma is accompanied by enhanced expression of the CD4 protein and messenger RNA. *Immunology*. 1992 May;76(1):55-9. PMID:1628901; PMCID: PMC1421760.

IF 2002: 2,729

6: Botto M, Lissandrini D, Sorio C, Walport MJ. Biosynthesis and secretion of complement component (C3) by activated human polymorphonuclear leukocytes. *J Immunol*. 1992 Aug 15;149(4):1348-55. PMID: 1500721.

IF 2002: 7,014

7: Vinante F, Pizzolo G, Rigo A, Vincenzi C, Sorio C, Cassatella M, Berton G. The CD4 molecule belongs to the phenotypic repertoire of most cases of acute myeloid leukemia. *Leukemia*. 1992 Dec;6(12):1257-62. PMID: 1453771.

IF 2002: 4,693

8: Saggioro D, Sorio C, Calderazzo F, Callegaro L, Panozzo M, Berton G, Chieco-Bianchi L. Mechanism of action of the monosialoganglioside GM1 as a modulator of CD4 expression. Evidence that GM1-CD4 interaction triggers dissociation of p56lck from CD4, and CD4 internalization and degradation. *J Biol Chem*. 1993 Jan 15;268(2):1368-75. Erratum in: *J Biol Chem* 1993 Mar 15;268(8):6064. PMID:7678256.

IF 2002: 6,696

9: Sorio C, Saggioro D, Chieco-Bianchi L, Berton G. The monosialoganglioside GM1 induces internalisation and degradation of the CD4 antigen in U937 cells: evidence for a novel mechanism of CD4 down-modulation in a p56lck-negative cell line, which is independent of protein kinase C activation. *Biochem Biophys Res Commun*. 1993 Mar 31;191(3):1105-10. doi: 10.1006/bbrc.1993.1330. PMID: 8466487.

IF 2002: 2,935

10: Sorio C, Melotti P, Dusi S, Berton G. Interferon-gamma and tumor necrosis factor-alpha enhance p60src expression in human macrophages and myelomonocytic cell lines. *FEBS Lett*. 1993 Aug 2;327(3):315-20. doi:

10.1016/0014-5793(93)81012-o. PMID: 7688696.

IF 2002: 3,912

11: Berton G, Fumagalli L, Laudanna C, Sorio C. Beta 2 integrin-dependent protein tyrosine phosphorylation and activation of the FGR protein tyrosine kinase in human neutrophils. *J Cell Biol*. 1994 Aug;126(4):1111-21. doi:10.1083/jcb.126.4.1111. PMID: 7519620; PMCID: PMC2120114.

IF 2002: 12,522

12: Sorio C, Mendrola J, Lou Z, LaForgia S, Croce CM, Huebner K. Characterization of the receptor protein tyrosine phosphatase gene product PTPgamma: binding and activation by triphosphorylated nucleosides. *Cancer Res*. 1995 Nov 1;55(21):4855-64. PMID: 7585520.

IF 2002: 8,318

13: Prasad R, Yano T, Sorio C, Nakamura T, Rallapalli R, Gu Y, Leshkowitz D, Croce CM, Canaani E. Domains with transcriptional regulatory activity within the ALL1 and AF4 proteins involved in acute leukemia. *Proc Natl Acad Sci U S A*. 1995 Dec 19;92(26):12160-4. doi: 10.1073/pnas.92.26.12160. PMID: 8618864; PMCID: PMC40316.

IF 2002: 10,7

14: Chilosi M, Facchetti F, Dei Tos AP, Lestani M, Morassi ML, Martignoni G, Sorio C, Benedetti A, Morelli L, Doglioni C, Barberis M, Menestrina F, Viale G. bcl-2 expression in pleural and extrapleural solitary fibrous tumours. *J Pathol*. 1997 Apr;181(4):362-7. doi: 10.1002/(SICI)1096-9896(199704)181:4 PMID: 9196431.

IF 2002: 6,75

15: Ennas MG, Sorio C, Greim R, Nieddu M, Scarpa A, Orlandini S, Croce CM, Fey GH, Marschalek R. The human ALL-1/MLL/HRX antigen is predominantly localized in the nucleus of resting and proliferating peripheral blood mononuclear cells. *Cancer Res*. 1997 May 15;57(10):2035-41. PMID: 9158002.

IF 2002: 8,318

16: Sorio C, Melotti P, D'Arcangelo D, Mendrola J, Calabretta B, Croce CM, Huebner K. Receptor protein tyrosine phosphatase gamma, Ptp gamma, regulates hematopoietic differentiation. *Blood*. 1997 Jul 1;90(1):49-57. PMID: 9207437.

IF 2002: 9,631

17: Yano T, Nakamura T, Blechman J, Sorio C, Dang CV, Geiger B, Canaani E. Nuclear punctate distribution of ALL-1 is conferred by distinct elements at the N terminus of the protein. *Proc Natl Acad Sci U S A*. 1997 Jul 8;94(14):7286-91. doi: 10.1073/pnas.94.14.7286. PMID: 9207083; PMCID: PMC23813.
IF 2002:10,7

18: Chilosi M, Doglioni C, Yan Z, Lestani M, Menestrina F, Sorio C, Benedetti A, Vinante F, Pizzolo G, Inghirami G. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. *Am J Pathol*. 1998 Jan;152(1):209-17. PMID: 9422538; PMCID: PMC1858129.
IF 2002: 6,75

19: Sorio C, Baron A, Orlandini S, Zamboni G, Pederzoli P, Huebner K, Scarpa A. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. *Cancer Res*. 1999 Mar 15;59(6):1308-14. PMID: 10096564.
IF 2002: 8,318

20: Wallrapp C, Hölzel S, Boeck W, Soder A, Mincheva A, Lichter P, Leder G, Gansauge F, Sorio C, Scarpa A, Gress TM. Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis. *Int. J. Cancer* 2001 Feb 1;91(3):340-4. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1014>3.0.co;2-u. PMID: 11169957.
IF 2002: 4,056

21: Cattaneo M, Sorio C, Malferrari G, Rogozin IB, Bernard L, Scarpa A, Zollo M, Biunno I. Cloning and functional analysis of SEL1L promoter region, a pancreas-specific gene. *DNA Cell Biol*. 2001 Jan;20(1):1-9. doi: 10.1089/10445490150504648. PMID: 11242538.
IF 2002: 1,771

22: Sorio C, Bonora A, Orlandini S, Moore PS, Capelli P, Cristofori P, Dal Negro G, Marchiori P, Gaviraghi G, Falconi M, Pederzoli P, Zamboni G, Scarpa A. Successful xenografting of cryopreserved primary pancreatic cancers. *Virchows Arch*. 2001 Feb;438(2):154-8. doi: 10.1007/s004280000343. PMID: 11253117.
IF 2002: 2,045

23: Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Klöppel G, Kalthoff H, Ungefroren H, Lühr M, Scarpa A. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. *Virchows Arch*. 2001 Dec;439(6):798-802. doi: 10.1007/s004280100474. PMID: 11787853.
IF 2002: 2,045

24: Marcucci S, Bonora A, Falconi M, Sorio C, Orlandini S, Beghelli S, Cristofori P, Dal Negro G, Marchiori PN, Bassi C, Scarpa A, Pederzoli P. Progetto integrato per la ricerca traslazionale nel carcinoma duttale del pancreas [Integrated project for the translational research on pancreatic ductal carcinoma]. *Chir Ital*. 2002 Nov-Dec;54(6):845-54. Italian. PMID: 12613334.

25: Laudanna C, Sorio C, Tecchio C, Butcher EC, Bonora A, Bassi C, Scarpa A. Motility analysis of pancreatic adenocarcinoma cells reveals a role for the atypical zeta isoform of protein kinase C in cancer cell movement. *Lab Invest*. 2003 Aug;83(8):1155-63. doi: 10.1097/01.lab.0000081390.92179.f3. PMID: 12920244.
IF: 4,418

26: Cattaneo M, Orlandini S, Beghelli S, Moore PS, Sorio C, Bonora A, Bassi C, Talamini G, Zamboni G, Orlandi R, Minard S, Bernardi LR, Biunno I, Scarpa A. SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo. *Oncogene*. 2003 Sep 25;22(41):6359-68. doi: 10.1038/sj.onc.1206665. PMID: 14508516.
IF: 6,495

27: Liu S, Sugimoto Y, Sorio C, Tecchio C, Lin YC. Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7. *Oncogene*. 2004 Feb 12;23(6):1256-62. doi: 10.1038/sj.onc.1207235. PMID: 14676845.
IF: 6,318

28: Sorio C, Moore PS, Ennas MG, Tecchio C, Bonora A, Sartoris S, Balzarini P, Grigolato P, Scarpa A. A novel cell line and xenograft model of ampulla of Vater adenocarcinoma. *Virchows Arch*. 2004 Mar;444(3):269-77. doi: 10.1007/s00428-003-0936-6. Epub 2003 Dec 16. PMID: 14677066.

IF: 2,227

29: Sorio C, Capelli P, Lissandrini D, Moore PS, Balzarini P, Falconi M, Zamboni G, Scarpa A. Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion. *Virchows Arch.* 2005 Mar;446(3):239-45. doi: 10.1007/s00428-004-1167-1. Epub 2005 Feb 2. PMID: 15688169.

IF: 2,224

30: Mauri P, Scarpa A, Nascimbeni AC, Benazzi L, Parmagnani E, Mafficini A, Della Peruta M, Bassi C, Miyazaki K, Sorio C. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. *FASEB J.* 2005 Jul;19(9):1125-7. doi: 10.1096/fj.04-3000fje. Epub 2005 May 4. PMID: 15985535.

IF: 7,064

31: Sorio C, Mauri P, Pederzoli P, Scarpa A. Non-invasive cancer detection: strategies for the identification of novel cancer markers. *IUBMB Life.* 2006 Apr;58(4):193-8. doi: 10.1080/15216540600719598. PMID: 16754296.

IF: 2,316

32: Lissandrini D, Vermi W, Vezzalini M, Sozzani S, Facchetti F, Bellone G, Mafficini A, Gentili F, Ennas MG, Tecchio C, Sorio C. Receptor-type protein tyrosine phosphatase gamma (PTPgamma), a new identifier for myeloid dendritic cells and specialized macrophages. *Blood.* 2006 Dec 15;108(13):4223-31. doi: 10.1182/blood-2006-05-024257. Epub 2006 Aug 8. PMID: 16896153.

IF: 10,37

33: Bellone G, Carbone A, Smirne C, Scirelli T, Buffolino A, Novarino A, Stacchini A, Bertetto O, Palestro G, Sorio C, Scarpa A, Emanuelli G, Rodeck U. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. *J Immunol.* 2006 Sep 1;177(5):3448-60. doi: 10.4049/jimmunol.177.5.3448. PMID: 16920987.

IF: 6,293

34: Mafficini A, Vezzalini M, Zamai L, Galeotti L, Bergamini G, Della Peruta M, Melotti P, Sorio C. Protein Tyrosine Phosphatase Gamma (PTPgamma) is a Novel Leukocyte Marker Highly Expressed by CD34 Precursors. *Biomark Insights.* 2007 May 31;2:218-25. PMID: 19662205; PMCID: PMC2717823.

IF 2013: 2,42

35: Vezzalini M, Mombello A, Menestrina F, Mafficini A, Della Peruta M, van Niekerk C, Barbareschi M, Scarpa A, Sorio C. Expression of transmembrane protein tyrosine phosphatase gamma (PTPgamma) in normal and neoplastic human tissues. *Histopathology.* 2007 Apr;50(5):615-28. doi: 10.1111/j.1365-2559.2007.02661.x. PMID: 17394498.

IF: 3,791

36: Saraga G, Mafficini A, Ghaneh P, Sorio C, Costello E. Both HIV- and EIAV- based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts. *Cancer Gene Ther.* 2007 Sep;14(9):781-90. doi: 10.1038/sj.cgt.7701066. Epub 2007 Jun 15. PMID: 17571071.

IF: 3,889

37: Bergamini G, Cigana C, Sorio C, Della Peruta M, Pompella A, Corti A, Huaux FA, Leal T, Assael BM, Melotti P. Effects of azithromycin on glutathione S-transferases in cystic fibrosis airway cells. *Am J Respir Cell Mol Biol.* 2009 Aug;41(2):199-206. doi: 10.1165/rcmb.2008-0013OC. Epub 2008 Dec 18. PMID: 19097986.

IF: 4,319

38: Sorio C, Melotti P. Editorial: The role of macrophages and their scavenger receptors in cystic fibrosis. *J Leukoc Biol.* 2009 Sep;86(3):465-8. doi: 10.1189/jlb.0309120. PMID: 19720614.

IF: 4.403

39: Monsurrò V, Beghelli S, Wang R, Barbi S, Coin S, Di Pasquale G, Bersani S, Castellucci M, Sorio C, Eleuteri S, Worschech A, Chiorini JA, Pederzoli P, Alter H, Marincola FM, Scarpa A. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. *J Transl Med.* 2010 Jan 29;8:10. doi: 10.1186/1479-5876-8-10. PMID: 20113473; PMCID: PMC2845551.

IF: 3,508

- 40: Della Peruta M, Giagulli C, Laudanna C, Scarpa A, Sorio C. RHOA and PRKCZ control different aspects of cell motility in pancreatic cancer metastatic clones. *Mol Cancer*. 2010 Mar 17;9:61. doi: 10.1186/1476-4598-9-61. PMID: 20236512; PMCID: PMC2846889.
IF: 3,779
- 41: Bellisola G, Della Peruta M, Vezzalini M, Moratti E, Vaccari L, Birarda G, Piccinini M, Cinque G, Sorio C. Tracking infrared signatures of drugs in cancer cells by Fourier transform microspectroscopy. *Analyst*. 2010 Dec;135(12):3077-86. doi: 10.1039/c0an00509f. Epub 2010 Oct 7. PMID: 20931110.
IF: 3,913
- 42: Della Peruta M, Martinelli G, Moratti E, Pintani D, Vezzalini M, Mafficini A, Grafone T, Iacobucci I, Soverini S, Murineddu M, Vinante F, Tecchio C, Piras G, Gabbas A, Monne M, Sorio C. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. *Cancer Res*. 2010 Nov 1;70(21):8896-906. doi: 10.1158/0008-5472.CAN-10-0258. Epub 2010 Oct 19. PMID: 20959494.
IF: 8,234
- 43: Vezzalini M, Aletta JM, Beghelli S, Moratti E, Della Peruta M, Mafficini A, Mojica WD, Mombello A, Scarpa A, Sorio C. Immunohistochemical detection of arginine methylated proteins (MeRP) in archival tissues. *Histopathology*. 2010 Nov;57(5):725-33. doi: 10.1111/j.1365-2559.2010.03684.x. PMID: 21083602.
IF: 3,569
- 44: Mafficini A, Ortombina M, Sermet-Gaudelius I, Lebecque P, Leal T, Iansa P, Reyhler G, Dahan K, Pepermans X, Lenoir G, Leonard A, Sorio C, Assael B, Melotti P. Impact of polymorphism of Multidrug Resistance-associated Protein 1 (ABCC1) gene on the severity of cystic fibrosis. *J Cyst Fibros*. 2011 Jul;10(4):228-33. doi: 10.1016/j.jcf.2010.10.007. Epub 2011 Mar 24. PMID: 21435954.
IF: 3,19
- 45: Chatterjee I, Humtsoe JO, Kohler EE, Sorio C, Wary KK. Lipid phosphate phosphatase-3 regulates tumor growth via beta-catenin and CYCLIN-D1 signaling. *Mol Cancer*. 2011 May 11;10:51. doi: 10.1186/1476-4598-10-51. PMID: 21569306; PMCID: PMC3112429.
IF: 3,993
- 46: Sorio C, Buffelli M, Angiari C, Ettore M, Johansson J, Vezzalini M, Viviani L, Ricciardi M, Verzè G, Assael BM, Melotti P. Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis. *PLoS One*. 2011;6(7):e22212. doi: 10.1371/journal.pone.0022212. Epub 2011 Jul 21. PMID: 21811577; PMCID: PMC3141019.
IF: 4,092
- 47: Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G, Blasi F, Talamini G, Bassi C, Scarpa A. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. *BMC Cancer*. 2011 Oct 14;11:448. doi: 10.1186/1471-2407-11-448. PMID: 21999221; PMCID: PMC3213238.
IF: 3,011
- 48: Bellisola G, Sorio C. Infrared spectroscopy and microscopy in cancer research and diagnosis. *Am J Cancer Res*. 2012;2(1):1-21. Epub 2011 Nov 22. PMID: 22206042; PMCID: PMC3236568.
IF: 3,968
- 49: Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, Iuliano L, Piroddi M, Dehecchi MC, Cabrini G; Working Group on Inflammation in Cystic Fibrosis. Oxidative stress and antioxidant therapy in cystic fibrosis. *Biochim Biophys Acta*. 2012 May;1822(5):690-713. doi: 10.1016/j.bbadis.2011.12.012. Epub 2011 Dec 28. Erratum in: *Biochim Biophys Acta*. 2014 Dec;1842(12):2531. PMID: 22226887.
IF: 5,089
- 50: Bergamini G, Di Silvestre D, Mauri P, Cigana C, Bragonzi A, De Palma A, Benazzi L, D'Aring G, Assael BM, Melotti P, Sorio C. MudPIT analysis of released proteins in *Pseudomonas aeruginosa* laboratory and clinical strains in relation to pro-inflammatory effects. *Integr Biol (Camb)*. 2012 Mar;4(3):270-9. doi: 10.1039/c2ib00127f. Epub 2012 Feb 1. PMID: 22298109.
IF: 3,996

- 51: Bellisola G, Cinque G, Vezzalini M, Moratti E, Silvestri G, Redaelli S, Gambacorti Passerini C, Wehbe K, Sorio C. Rapid recognition of drug- resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis. *Analyst*. 2013 Jul 21;138(14):3934-45. doi: 10.1039/c2an36393c. PMID: 23323262.
IF: 3,906
- 52: Sorio C, Angiari C, Johansson J, Verzè G, Ettore M, Buffelli M, Castellani C, Assael BM, Melotti P. Impaired CFTR function in mild cystic fibrosis associated with the S977F/T5TG12complex allele in trans with F508del mutation. *J Cyst Fibros*. 2013 Dec;12(6):821-5. doi: 10.1016/j.jcf.2012.12.014. Epub 2013 Jan 27. PMID: 23361109.
IF: 3,82
- 53: Lorenzetto E, Moratti E, Vezzalini M, Harroch S, Sorio C, Buffelli M. Distribution of different isoforms of receptor protein tyrosine phosphatase gamma(Ptprg-RPTP γ) in adult mouse brain: upregulation during neuroinflammation. *Brain Struct Funct*. 2014 May;219(3):875-90. doi: 10.1007/s00429-013-0541-7. Epub 2013 Mar 28. PMID: 23536318.
IF: 5,618
- 54: Caldrier S, Verzè G, Johansson J, Sorio C, Angiari C, Buffelli M, Assael BM, Melotti P. Challenging the diagnosis of cystic fibrosis in a patient carrying the 186-8T/C allelic variant in the CF transmembrane conductance regulator gene. *BMC Pulm Med*. 2014 Mar 13;14:44. doi: 10.1186/1471-2466-14-44. PMID: 24621136; PMCID: PMC3995624.
IF: 2,404
- 55: Johansson J, Vezzalini M, Verzè G, Caldrier S, Bolognin S, Buffelli M, Bellisola G, Tridello G, Assael BM, Melotti P, Sorio C. Detection of CFTR protein in human leukocytes by flow cytometry. *Cytometry A*. 2014 Jul;85(7):611-20. doi: 10.1002/cyto.a.22456. Epub 2014 Mar 12. PMID: 24623386.
IF: 2,928
- 56: Ettore M, Verzè G, Caldrier S, Johansson J, Calcaterra E, Assael BM, Melotti P, Sorio C, Buffelli M. Electrophysiological evaluation of cystic fibrosis conductance transmembrane regulator (CFTR) expression in human monocytes. *Biochim Biophys Acta*. 2014 Oct;1840(10):3088-95. doi: 10.1016/j.bbagen.2014.07.010. Epub 2014 Jul 18. PMID: 25046381.
IF: 4,381
- 57: Galvan A, Colombo F, Frullanti E, Dassano A, Noci S, Wang Y, Eisen T, Matakidou A, Tomasello L, Vezzalini M, Sorio C, Dugo M, Ambrogi F, Iacobucci I, Martinelli G, Incarbone M, Alloisio M, Nosotti M, Tosi D, Santambrogio L, Pelosi G, Pastorino U, Houlston RS, Dragani TA. Germline polymorphisms and survival of lung adenocarcinoma patients: a genome-wide study in two European patient series. *Int. J. Cancer* 2015 Mar 1;136(5):E262-71. doi: 10.1002/ijc.29195. Epub 2014 Sep 19. PMID: 25196286.
IF: 5,531
- 58: Melotti P, Mafficini A, Lebecque P, Ortombina M, Leal T, Pintani E, Pepermans X, Sorio C, Assael BM. Impact of MIF gene promoter polymorphism on F508del cystic fibrosis patients. *PLoS One*. 2014 Dec 12;9(12):e114274. doi: 10.1371/journal.pone.0114274. PMID: 25503271; PMCID: PMC4264759.
IF: 3,234
- 59: Mirenda M, Toffali L, Montresor A, Scardoni G, Sorio C, Laudanna C. Protein tyrosine phosphatase receptor type gamma is a JAK phosphatase and negatively regulates leukocyte integrin activation. *J Immunol*. 2015 Mar 1;194(5):2168-79. doi: 10.4049/jimmunol.1401841. Epub 2015 Jan 26. PMID: 25624455.
IF: 4,985
- 60: Moratti E, Vezzalini M, Tomasello L, Giavarina D, Sorio C. Identification of protein tyrosine phosphatase receptor gamma extracellular domain (sPTPRG) as a natural soluble protein in plasma. *PLoS One*. 2015 Mar 16;10(3):e0119110. doi:10.1371/journal.pone.0119110. PMID: 25775014; PMCID: PMC4361625.
IF: 3,057
- 61: Bellisola G, Bolomini Vittori M, Cinque G, Dumas P, Fiorini Z, Laudanna C, Mirenda M, Sandt C, Silvestri G, Tomasello L, Vezzalini M, Wehbe K, Sorio C. Unsupervised explorative data analysis of normal human leukocytes and BCR/ABL positive leukemic cells mid-infrared spectra. *Analyst*. 2015 Jul 7;140(13):4407-22. doi: 10.1039/c5an00148j. PMID: 25988195.
IF: 4,033

- 62: Pore N, Jalla S, Liu Z, Higgs B, Sorio C, Scarpa A, Hollingsworth R, Tice DA, Michelotti E. In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors. *Neoplasia*. 2015 Jun;17(6):473-80. doi: 10.1016/j.neo.2015.05.001. PMID: 26152355; PMCID: PMC4719001. IF: 4,509
- 63: Stellari F, Bergamini G, Sandri A, Donofrio G, Sorio C, Ruscitti F, Villetti G, Assael BM, Melotti P, Lleo MM. In vivo imaging of the lung inflammatory response to *Pseudomonas aeruginosa* and its modulation by azithromycin. *J Transl Med*. 2015 Aug 4;13:251. doi: 10.1186/s12967-015-0615-9. PMID: 26239109; PMCID: PMC4522964. IF: 3,964
- 64: Sorio C*, Montresor A, Bolomini-Vittori M, Calderr S, Rossi B, Dusi S, Angiari S, Johansson JE, Vezzalini M, Leal T, Calcaterra E, Assael BM, Melotti P, Laudanna C. Mutations of Cystic Fibrosis Transmembrane Conductance Regulator Gene Cause a Monocyte-Selective Adhesion Deficiency. *Am J Respir Crit Care Med*. 2016 May 15;193(10):1123-33. doi: 10.1164/rccm.201510-1922OC. PMID: 26694899.
* corresponding author IF: 13,204
- 65: Rizzo R, Bergamini G, Bortolotti D, Leal T, D'Orazio C, Pintani E, Melchiorri L, Zavatti E, Assael BM, Sorio C, Melotti P. HLA-G expression and regulation during *Pseudomonas aeruginosa* infection in cystic fibrosis patients. *Future Microbiol*. 2016;11(3):363-73. doi: 10.2217/fmb.15.143. Epub 2016 Mar 2. PMID: 26934639. IF: 3,374
- 66: Lai ZW, Bolm L, Fuellgraf H, Binossek ML, Makowiec F, Hopt UT, Werner M, Keck T, Bausch D, Sorio C, Scarpa A, Schilling O, Bronsert P, Wellner UF. Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses. *BMC Cancer*. 2016 Mar 8;16:195. doi: 10.1186/s12885-016-2193-5. PMID: 26951071; PMCID: PMC4782372. IF: 3,288
- 67: Stellari F, Bergamini G, Ruscitti F, Sandri A, Ravanetti F, Donofrio G, Boschi F, Villetti G, Sorio C, Assael BM, Melotti P, Lleo MM. In vivo monitoring of lung inflammation in CFTR-deficient mice. *J Transl Med*. 2016 Jul 28;14(1):226. doi: 10.1186/s12967-016-0976-8. PMID: 27468800; PMCID: PMC4964274. IF: 3,786
- 68: Bezzerri V, Vella A, Calcaterra E, Finotti A, Gasparello J, Gambari R, Assael BM, Cipolli M, Sorio C. New insights into the Shwachman-Diamond Syndrome- related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes. *Sci Rep*. 2016 Sep 23;6:33165. doi: 10.1038/srep33165. PMID: 27658964; PMCID: PMC5034238. IF: 4,259
- 69: Lecca P, Sorio C. Accurate prediction of the age incidence of chronic myeloid leukemia with an improved two-mutation mathematical model. *Integr Biol (Camb)*. 2016 Dec 5;8(12):1261-1275. doi: 10.1039/c6ib00127k. PMID: 27801472. IF: 3,252
- 70: Leal T, Bergamini G, Huaux F, Panin N, Noel S, Dhooghe B, Haaf JB, Mauri P, Motta S, Di Silvestre D, Melotti P, Sorio C. Azithromycin Attenuates *Pseudomonas aeruginosa* Induced Lung Inflammation by Targeting Bacterial Proteins Secreted in the Cultured Medium. *Front Immunol*. 2016 Nov 15;7:499. doi: 10.3389/fimmu.2016.00499. PMID: 27895643; PMCID: PMC5108761. 85006121555 IF: 6,429
- 71: Vezzalini M, Mafficini A, Tomasello L, Lorenzetto E, Moratti E, Fiorini Z, Holyoake TL, Pellicano F, Krampera M, Tecchio C, Yassin M, Al-Dewik N, Ismail MA, Al Sayab A, Monne M, Sorio C. A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type gamma in chronic myeloid leukemia patients. *J Hematol Oncol*. 2017 Jun 21;10(1):129. doi: 10.1186/s13045-017-0494-z. PMID: 28637510; PMCID: PMC5479035. IF: 6,35
- 72: Bergamini G, Stellari F, Sandri A, M Lleo M, Donofrio G, Ruscitti F, Boschi F, Sbarbati A, Villetti G, Melotti P, Sorio C. An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses. *J Vis Exp*. 2017 Jul 7;(125):55499. doi: 10.3791/55499. PMID: 28715404; PMCID: PMC5609320. IF: 1,232
- 73: Franca R, Kuzelicki NK, Sorio C, Toffoletti E, Montecchini O, Poropat A, Rabusin M, Curci D, Paladin D, Stocco G, Decorti G. Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia. *Curr Med Chem*. 2018;25(24):2811-2825. doi: 10.2174/0929867324666170727101932. PMID: 28748759.

IF: 3,249

74: Gohil SH, Paredes-Moscosso SR, Harrasser M, Vezzalini M, Scarpa A, Morris E, Davidoff AM, Sorio C, Nathwani AC, Della Peruta M. An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors. *Oncoimmunology*. 2017 May 17;6(7):e1326437. doi: 10.1080/2162402X.2017.1326437. PMID: 28811962; PMCID: PMC5543882.

IF: 7,719

75: Bezzerri V, Bardelli D, Morini J, Vella A, Cesaro S, Sorio C, Biondi A, Danesino C, Farruggia P, Assael BM, D'amico G, Cipolli M. Ataluren-driven restoration of Shwachman-Bodian-Diamond syndrome protein function in Shwachman-Diamond syndrome bone marrow cells. *Am J Hematol*. 2018 Aug;93(4):527-536. doi: 10.1002/ajh.25025. Epub 2018 Feb 9. PMID: 29285795.

IF: 5,275

76: Bergamini G, Tridello G, Calcaterra E, Ceri S, Tagliasacchi M, Bianchi F, Monti F, Masciadri A, Laudanna E, Peserico D, Sorio E, Esposito V, Leal T, Assael BM, Sorio C, Melotti P. Ratiometric sweat secretion optical test in cystic fibrosis, carriers and healthy subjects. *J Cyst Fibros*. 2018 Mar;17(2):186-189. doi: 10.1016/j.jcf.2017.12.003. Epub 2017 Dec 29. PMID: 29292091.

IF: 4,727

77: Drube J, Ernst T, Pfirrmann M, Albert BV, Drube S, Reich D, Kresinsky A, Halfter K, Sorio C, Fabisch C, Hochhaus A, Bohmer FD. PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells. *Oncotarget*. 2018 Jan 15;9(10):9442-9455. doi: 10.18632/oncotarget.24253. PMID: 29507701; PMCID: PMC5823647.

IF: 5,168

78: Sandri A, Ortombina A, Boschi F, Cremonini E, Boaretti M, Sorio C, Melotti P, Bergamini G, Lleo M. Inhibition of *Pseudomonas aeruginosa* secreted virulence factors reduces lung inflammation in CF mice. *Virulence*. 2018;9(1):1008-1018. doi: 10.1080/21505594.2018.1489198. PMID: 29938577; PMCID: PMC6086295.

IF: 4,665

79: Gramegna A, Aliberti S, Seia M, Porcaro L, Bianchi V, Castellani C, Melotti P, Sorio C, Consalvo E, Franceschi E, Amati F, Contarini M, Gaffuri M, Roncoroni L, Vigone B, Bellofiore A, Del Monaco C, Oriano M, Terranova L, Patria MF, Marchisio P, Assael BM, Blasi F. When and how ruling out cystic fibrosis in adult patients with bronchiectasis. *Multidiscip Respir Med*. 2018 Aug 9;13(Suppl 1):29. doi: 10.1186/s40248-018-0142-7. PMID: 30151190; PMCID: PMC6101074.

IF: 0,609

80: Caldreer S, Bergamini G, Sandri A, Vercellone S, Rodella L, Cerofolini A, Tomba F, Catalano F, Frulloni L, Buffelli M, Tridello G, de Jonge H, Assael BM, Sorio C, Melotti P. Cystic fibrosis transmembrane conductance regulator functional evaluations in a G542X+/- IVS8Tn:T7/9 patient with acute recurrent pancreatitis. *World J Clin Cases*. 2019 Nov 26;7(22):3757-3764. doi: 10.12998/wjcc.v7.i22.3757. PMID: 31799301; PMCID: PMC6887611.

I.F. 1.013

81: Vella A, D'Aversa E, Api M, Breveglieri G, Allegri M, Giacomazzi A, Marinelli Busilacchi E, Fabrizzi B, Cestari T, Sorio C, Bedini G, D'Amico G, Bronte V, Poloni A, Benedetti A, Bovo C, Corey SJ, Borgatti M, Cipolli M, Bezzerri V. mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment. *Cancers (Basel)*. 2020 Mar 5;12(3):597. doi: 10.3390/cancers12030597. PMID: 32150944; PMCID: PMC7139896.

I.F. 6.639

82: Tomasello L, Vezzalini M, Boni C, Bonifacio M, Scaffidi L, Yassin M, Al-Dewik N, Takam Kanga P, Krampera M, Sorio C. Regulative Loop between beta-catenin and Protein Tyrosine Receptor Type gamma in Chronic Myeloid Leukemia. *Int. J. Mol. Sci*. 2020 Mar 26;21(7):2298. doi: 10.3390/ijms21072298. PMID: 32225105; PMCID: PMC7177637.

I.F. 5.924

83: Ismail MA, Samara M, Al Sayab A, Alsharshani M, Yassin MA, Varadharaj G, Vezzalini M, Tomasello L, Monne M, Morsi H, Qoronfleh MW, Zayed H, Cook R, Sorio C, Modjtahedi H, Al-Dewik NI. Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar. *Mol Genet Genomic Med*. 2020 Oct;8(10):e1319. doi: 10.1002/mgg3.1319. Epub 2020 Jul 23. PMID: 32700424; PMCID: PMC7549574.

I.F. 2.473

- 84: Piaggi S, Marchi E, Carnicelli V, Zucchi R, Griese M, Hector A, Sorio C, Pompella A, Corti A. Airways glutathione S-transferase omega-1 and its A140D polymorphism are associated with severity of inflammation and respiratory dysfunction in cystic fibrosis. *J Cyst Fibros.* 2021 Nov;20(6):1053-1061. doi: 10.1016/j.jcf.2021.01.010. Epub 2021 Feb 12. PMID: 33583732.
I.F. 5.527
- 85: Treggiari D, Kleinfelder K, Bertini M, Tridello G, Fedrigo A, Pintani E, Iansa P, Casiraghi A, Minghetti P, Cipolli M, Sorio C, Melotti P. Optical Measurements of Sweat for in Vivo Quantification of CFTR Function in Individual Sweat Glands. *J Cyst Fibros.* 2021 Sep;20(5):824-827. doi: 10.1016/j.jcf.2021.03.003. Epub 2021 Apr 2. PMID: 33814321.
I.F. 5.527
- 86: Ismail MA, Vezzalini M, Morsi H, Abujaber A, Al Sayab A, Siveen K, Yassin MA, Monne M, Samara M, Cook R, Sorio C, Modjtahedi H, Al-Dewik NI. Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients. *Sci Rep.* 2021 Apr 23;11(1):8833. doi: 10.1038/s41598-021-86875-y. PMID: 33893334; PMCID: PMC8065106.
I.F. 4,996
- 87: Pedrazzi M, Vercellone S, Barberis E, Capraro M, De Tullio R, Cresta F, Casciaro R, Castellani C, Patrone M, Marengo E, Lecca P, Melotti P, Sorio C, Manfredi M, Averna M. Identification of Potential Leukocyte Biomarkers Related to Drug Recovery of CFTR: Clinical Applications in Cystic Fibrosis. *Int. J. Mol. Sci.* 2021 Apr 10;22(8):3928. doi: 10.3390/ijms22083928. PMID: 33920274; PMCID: PMC8068931.
I.F. 6,208
- 88: Boni C, Sorio C. Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia. *Cancers (Basel).* 2021 May12;13(10):2311. doi: 10.3390/cancers13102311. PMID: 34065882; PMCID: PMC8151247.
I.F. 6.575
- 89: Abdulla MAJ, Chandra P, Akiki SE, Aldapt MB, Sardar S, Chapra A, Nashwan AJ, Sorio C, Tomasello L, Boni C, Yassin MA. Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project. *Cancer Control.* 2021 Jan-Dec;28:10732748211038429. doi: 10.1177/10732748211038429. PMID: 34789006; PMCID: PMC8619745.
I.F. 2.339
- 90: Montecchini O, Braidotti S, Franca R, Zudeh G, Boni C, Sorio C, Toffoletti E, Rabusin M, Tommasini A, Decorti G, Stocco G. A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity *in vitro*: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias. *Front Pharmacol.* 2021 Nov 19;12:749361. doi: 10.3389/fphar.2021.749361. PMID: 34867354; PMCID: PMC8640483.
I.F. 5.998
- 91: Ismail MA, Nasrallah GK, Monne M, AlSayab A, Yassin MA, Varadharaj G, Younes S, Sorio C, Cook R, Modjtahedi H, Al-Dewik NI. Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors. *Gene.* 2022 Mar 1;813:146101. doi: 10.1016/j.gene.2021.146101. Epub 2021 Dec 11. PMID: 34906644.
I.F. 3.913
- 92: Averna M, Melotti P, Sorio C. Revisiting the Role of Leukocytes in Cystic Fibrosis. *Cells.* 2021 Dec 1;10(12):3380. doi: 10.3390/cells10123380. PMID: 34943888; PMCID: PMC8699441.
I.F. 7,666
- 93: Boni C, Laudanna C, Sorio C. A Comprehensive Review of Receptor-Type Tyrosine-Protein Phosphatase Gamma (PTPRG) Role in Health and Non-Neoplastic Disease. *Biomolecules.* 2022 Jan 6;12(1):84. doi: 10.3390/biom12010084. PMID: 35053232; PMCID: PMC8773835.
I.F. 5.5
- 94: Boni C, Sorio C. The Role of the Tumor Suppressor Gene Protein Tyrosine Phosphatase Gamma in Cancer. *Front Cell Dev Biol.* 2022 Jan 5;9:768969. doi: 10.3389/fcell.2021.768969. PMID: 35071225; PMCID: PMC8766859.
I.F. 5.5
- 95: Ghigo A, Murabito A, Sala V, Pisano AR, Bertolini S, Gianotti A, Caci E, Montresor A, Premchandrar A, Pirozzi F, Ren K, Della Sala A, Mergioti M, Richter W, de Poel E, Matthey M, Caldres S, Cardone RA, Civiletti F, Costamagna A, Quinney NL, Butnarasu C, Visentin S, Ruggiero MR, Baroni S, Crich SG, Ramel D, Laffargue M, Tocchetti CG, Levi R,

Conti M, Lu XY, Melotti P, Sorio C, De Rose V, Facchinetti F, Fanelli V, Wenzel D, Fleischmann BK, Mall MA, Beekman J, Laudanna C, Gentzsch M, Lukacs GL, Pedemonte N, Hirsch E. A PI3K α mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases. *Sci Transl Med*. 2022 Mar 30;14(638):eabl6328. doi: 10.1126/scitranslmed.abl6328. Epub 2022 Mar 30. PMID: 35353541.

I.F. 17.1

96: Ciciriello F, Bijvelds MJC, Alghisi F, Meijssen KF, Cristiani L, Sorio C, Melotti P, Focchi AG, Lucidi V, De Jonge HR. Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers. *J Pers Med*. 2022 Apr 14;12(4):632. doi: 10.3390/jpm12040632. PMID: 35455747; PMCID: PMC9027586.

I.F. 3.5

97: Lotti V, Merigo F, Lagni A, Di Clemente A, Ligozzi M, Bernardi P, Rossini G, Concia E, Plebani R, Romano M, Sbarbati A, Sorio C, Gibellini D. CFTR Modulation Reduces SARS-CoV-2 Infection in Human Bronchial Epithelial Cells. *Cells*. 2022 Apr 15;11(8):1347. doi: 10.3390/cells11081347. PMID: 35456026; PMCID: PMC9028056.

I.F. 6

98: Boni C, Bonifacio M, Vezzalini M, Scaffidi L, Tomasello L, Parker LL, Boscarino D, Paladin D, Krampera M, Sorio C. Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity. *Front Oncol*. 2022 Jun 8;12:904510. doi: 10.3389/fonc.2022.904510. PMID: 35756686; PMCID: PMC9216732.

I.F. 4.2

99: Sandri A, Veschetti L, Saitta GM, Passarelli Mantovani R, Carelli M, Burlacchini G, Preato S, Sorio C, Melotti P, Montemari AL, Fiscarelli EV, Patuzzo C, Signoretto C, Boaretti M, Lleò MM, Malerba G. *Achromobacter* spp. Adaptation in Cystic Fibrosis Infection and Candidate Biomarkers of Antimicrobial Resistance. *Int. J. Mol. Sci*. 2022 Aug 17;23(16):9265. doi: 10.3390/ijms23169265. PMID: 36012535; PMCID: PMC9409262.

I.F. 5.6

100: Merigo F, Lotti V, Bernardi P, Conti A, Clemente AD, Ligozzi M, Lagni A, Sorio C, Sbarbati A, Gibellini D. Ultrastructural Characterization of Human Bronchial Epithelial Cells during SARS-CoV-2 Infection: Morphological Comparison of Wild-Type and CFTR-Modified Cells. *Int. J. Mol. Sci*. 2022 Aug 27;23(17):9724. doi: 10.3390/ijms23179724. PMID: 36077122; PMCID: PMC9455986.

I.F. 5.6

101: Lombardi G, Latorre RV, Mosca A, Calvanese D, Tomasello L, Boni C, Ferracin M, Negrini M, Dewik NA, Yassin M, Ismail MA, Carpentieri B, Sorio C, Lecca P. Gene Expression Landscape of Chronic Myeloid Leukemia K562 Cells Overexpressing the Tumor Suppressor Gene PTPRG. *Int. J. Mol. Sci*. 2022 Aug 31;23(17):9899. doi: 10.3390/ijms23179899. PMID: 36077295; PMCID: PMC9456469.

I.F. 5.6

102: Ismail MA, Sorio C, Al-Dewik N. Protein Tyrosine Phosphatase Receptor Gamma as Potential Therapeutic Target for Chronic Myeloid Leukemia Patients. *Cancer Control* 2022 Jan-Dec;29:10732748221140201. doi: 10.1177/10732748221140201. PMID: 36382578; PMCID: PMC9677154.

I.F. 2.6

103. Conti, J.; Sorio, C.; Melotti, P. Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis. *Children* 2023, 10, 4. <https://doi.org/10.3390/children10010004>

I.F. 2 (2023)

104. Lagni, A.; Lotti, V.; Diani, E.; Rossini, G., Concia, E., Sorio ,C. ‡ and Gibellini,D. ‡ CFTR Inhibitors Display In Vitro Antiviral Activity against SARS-CoV-2 Cells 2023, 12(5), 776; <https://doi.org/10.3390/cells12050776> ‡ equal contribution

I.F. 5.1 (2023)

105. Kleinfelder, K.; Somenza, E.; Farinazzo, A.; Conti, J.; Lotti, V.; Latorre, R.V.; Rodella, L.; Massella, A.; Tomba, F.; Bertini, M.; Sorio, C.*; Melotti, P.* CFTR Modulators Rescue the Activity of CFTR in Colonoids Expressing the Complex Allele p.[R74W;V201M;D1270N]/dele22_24. *Int. J. Mol. Sci*. 2023, 24, 5199. <https://doi.org/10.3390/ijms24065199>

*equal contribution

I.F. 4.9 (2023)

106. Lotti V, Lagni A, Diani E, Sorio C and Gibellini D (2023) Crosslink between SARS- CoV-2 replication and cystic fibrosis hallmarks. *Front. Microbiol*. 2023, 14:1162470. doi: 10.3389/fmicb.2023.1162470

I.F. 4 (2023)

107. Younes S, Ismail MA, Al-Jurf R, Ziyada A, Nasrallah GK, Abdulrouf PV, Nagy M, Zayed H, Farrell T, Sorio C, Morsi H, Qoronfleh MW, Al-Dewik NI. Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies. *Hematology*. 2023 Dec;28(1):2196866. doi: 10.1080/16078454.2023.2196866. I.F. 2 (2023)

108. Kleinfelder, K.; Villella, V.R.; Hristodor, A.M.; Laudanna, C.; Castaldo, G.; Amato, F.; Melotti, P.; Sorio, C. Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination. *Int. J. Mol. Sci.* 2023, 24, 10358. <https://doi.org/10.3390/ijms241210358> I.F. 4.9 (2023)

109. Kleinfelder, K., Lotti, V., Eramo, A., Amato, F., Lo Cicero, S., Castelli, G., Spadaro, F., Farinazzo, A., Dell'Orco, D., Preato, S., Conti, J., Rodella, L., Tomba, F., Cerofolini, A., Baldisseri, E., Bertini, M., Volpi, S., Villella, V.R., Esposito, S., Zollo, I., Castaldo, G., Laudanna, C., Sorsher, E.J, Hong, J., Joshi, D., Cutting, G., Lucarelli, M., Melotti, P., Sorio, C., In silico analysis and theratyping of an ultra-rare CFTR genotype (W57G/A234D) in primary human rectal and nasal epithelial cells, (2023), *iScience* 26, 108180, November 17, 2023 doi: <https://doi.org/10.1016/j.isci.2023.108180>. I.F. 4.6 (2023)

110. Lecca P, Lombardi G, Latorre RV and Sorio C (2023), How the latent geometry of a biological network provides information on its dynamics: the case of the gene network of chronic myeloid leukaemia. *Front. Cell Dev. Biol.* 11:1235116.doi: 10.3389/fcell.2023.1235116 I.F. 4.6 (2023)

111. Dora Angyal, Karina Kleinfelder, Fabiana Ciciriello, Tessa A. Groeneweg, Giulia De Marchi, Nicolò de Pretis, Laura Bernardoni, Luca Rodella, Francesco Tomba, Paola De Angelis, Cecilia Surace, Emily Pintani, Federico Alghisi, Hugo R. de Jonge, Paola Melotti, Claudio Sorio, Vincenzina Lucidi, Marcel J.C. Bijvelds, Luca Frulloni (2024) CFTR function is impaired in a subset of patients with pancreatitis carrying rare CFTR variants, *Pancreatology*, doi: 10.1016/j.pan.2024.03.005 I.F. 2.8 (2023)

112: Roberta Valeria Latorre, Martina Calicchia, Martina Bigliardi, Jessica Conti, Karina Kleinfelder , Paola Melotti, Claudio Sorio (2024) Functional rescue of CFTR in rectal organoids from patients carrying R334W variant by CFTR modulators and PDE4 inhibitor Roflumilast *Respiratory Investigation* 62 (2024) 455–461 doi:10.1016/j.resinv.2024.03.003 I.F. 2.4 (2023)

113: Merigo, F., Lagni, A.; Boschi, F., Bernardi, P., Conti, A., Plebani, R., Romano, M., Sorio, C., Lotti, V., Sbarbati, A. Loss of CFTR Reverses Senescence Hallmarks in SARS-CoV-2 Infected Bronchial Epithelial Cells. (2024) *Int. J.Mol.Sci.*,25,6185. <https://doi.org/10.3390/ijms25116185> I.F. 4.9 (2023)

114: Kleinfelder, K., Melotti, P., Hristodor, A.M., Fevola, C., Taccetti G., Terlizzi, V.* and Sorio, C. * "CFTR modulators response of S737F and T465N CFTR variants on patient-derived rectal organoids" (2024) *Orphanet Journal of Rare Diseases* doi.org/10.1186/s13023-024-03334-3 I.F. 3.4 (2023)

115. Fainardi V, Cresta F, Sorio C, Melotti, P., Pesce , E., Deolmi F.L., Kleinfelder, K., Esposito, S., Pisi, G. Elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis and rare mutations. *Pediatr Pulmonol.* 2024; 1-8. doi:10.1002/ppul.27211 I.F. 2.7 (2023)

Capitoli su libri

G. Berton, G. Poli and C. Sorio "Intracellular protein tyrosine kinases of the src family in mononuclear phagocytes",in "Mononuclear Phagocytes.Characteristics, Physiology and Functions"
Edited by: Vanfurth, R
Conference: 5TH LEIDEN CONF ON MONONUCLEAR PHAGOCYTES Location: LEIDEN, NETHERLANDS Date: MAY 13-16, 1991 Sponsor(s): ABN AMRO BANK; ASTRA PHARM; BAYER NEDERLAND; BOEHRINGER INGELHEIM PHARM; BRISTOL MYERS SQUIBB; CENTOCOR EUROPE; CIBA GEIGY; DELTA MED SCI INSTRUMENTS; GLAXO; ICI PHARM

Sorio, Claudio

MONONUCLEAR PHAGOCYTES: BIOLOGY OF MONOCYTES AND MACROPHAGES Pages: 500-507 Published: 1992

Sorio C, Bonora A, Orlandini S, Moore PS, Capelli P, Zamboni G, Cristofori P, Dal Negro G, Marchiori P, Gaviraghi G, Falconi M, Pederzoli P and Scarpa A. (2000). Establishment of a cryopreserved tissue bank and a xenografting facility for pancreatic cancer. Edited by: Gress, TM

Conference: Meeting on Molecular Pathogenesis of Pancreatic Cancer Location: BARCELONA, SPAIN Date: NOV, 1999 Molecular Pathogenesis of Pancreatic Cancer, pp. 45-48. Sponsor(s): European Union, BiomedII Programme
MOLECULAR PATHOGENESIS OF PANCREATIC CANCER Book Series: BIOMEDICAL AND HEALTH RESEARCH
Volume: 41 Pages: 45-48 Published: 2000

Wallrapp, C., S. Hahnel, C. Sorio, A. Scarpa and T. M. Gress (2000). Genomic RDA for the identification of chromosomal aberrations in pancreatic cancer: merits and drawbacks. Molecular Pathogenesis of Pancreatic Cancer. Edited by: Gress, TM

Conference: Meeting on Molecular Pathogenesis of Pancreatic Cancer Location: BARCELONA, SPAIN Date: NOV, 1999

Sponsor(s): European Union, BiomedII Programme

MOLECULAR PATHOGENESIS OF PANCREATIC CANCER Book Series: BIOMEDICAL AND HEALTH RESEARCH Volume: 41 Pages: 19-22 Published: 2000

Lissandrini, D ; Vermi, W ; Vezzadini, M; Sozzani, S; Facchetti, F; Mafficini, A; Sorio, C **Receptor type tyrosine phosphatase gamma (PTP gamma) is a novel dendritic cell marker**

Book Group Author(s): MEDIMOND

Conference: 12th Annual International Congress of Immunology/4th Annual Conference of the Federation-of-Clinical-Immunology-Societies (FOCIS) Location: Montreal, CANADA Date: JUL 18-23, 2004

Sponsor(s): Federat Clin Immunol Soc

IMMUNOLOGY 2004: GENOMIC ISSUES, IMMUNE SYSTEM ACTIVATION AND ALLERGY Pages: 407-412 Published: 2004

Bellisola, G. and Sorio, C., Tools for cancer research and diagnosis: infrared spectroscopy and microscopy in cancer research and diagnosis. DIAMOND LIGHT SOURCE ANNUAL REPORT 2012, pages 32-33

Massimiliano Bonifacio and Claudio Sorio Recent Developments in Chronic Myeloid Leukemia Biology and Treatment. April 2018 DOI10.2174/9781681083674118030004 In book: Frontiers in Clinical Drug Research: Hematology Volume 3 pp.29-72

eISBN: 978-1-68108-367-4, 2018; ISBN: 978-1-68108-368-1 ISSN: 2467-9585 (Print) ISSN: 2352-3239 (Online)

Lecca P, Lombardi G, Latorre RV and Sorio C. "How the latent geometry of a biological network provides information on its dynamics: the case of the gene network of chronic myeloid leukaemia" In Blinov ML and Mertins SD (2024) Editorial: Network-based mathematical modeling in cell and developmental biology. Front. Cell Dev. Biol. 12:1475005. doi: 10.3389/fcell.2024.1475005"

Brevetti

NOVEL BIOMARKERS FOR DIAGNOSIS AND/OR PROGNOSIS OF NEOPLASIAS IN ANIMALS

Application number: 20090130693 Issued: May 21, 2009

Inventors: Claudio Bassi, Pierluigi Mauri, Aldo Scarpa, Claudio Sorio

ANTIBODY AND METHOD FOR IDENTIFICATION OF DENDRITIC CELLS

20090131346 Issued: May 21, 2009

Assignee: CONSORZIO PER GLI STUDI UNIVERSITARI IN VERONA

Inventor: Claudio Sorio

DIAGNOSIS, PROGNOSIS AND/OR TREATMENT OF MYELOPROLIFERATIVE DISORDERS

Application number: WO2007085958 (A2), EP1987157 (A2)

Assignee: CONSORZIO PER GLI STUDI UNIVERSITARI IN VERONA

Inventors: Claudio Sorio

MONOCLONAL ANTIBODY FOR DIAGNOSING CHRONIC MYELOID LEUKEMIA

Provisional US patent application number: 62373322 filed on 10 August 2016

Assignee: Qatar Foundation

Sorio, Claudio

Inventors: Claudio Sorio: 40%; Dr. Nader Al-Dewik: 20%, Dr. Abdel Daem Mohamed Yassin: 20%, Dr. Marzia Vezzalini: 10%, Dr. Andrea Mafficini: 10%

Tampone di lisi per cellule e suoi usi in saggi per la rilevazione di una proteina cellulare o dell'attività di una proteina cellulare.

Lysis buffer for cells and uses for analysis of cell proteins or protein activity

Provisional ITALIAN patent application number: 102017000003916 filed on January, 16th 2017

Inventors: Claudio Sorio, Marzia Vezzalini

USE OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES FOR TREATING CYSTIC FIBROSIS

PCT/EP2018/085965 filed on December 19, 2018

C. Finanziamenti

Title of funded proposal: Ruolo della tirosin fosfatasi recettoriale gamma (PTPRG) sulla differenziazione emopoietica ed in cellule leucemiche, cellule staminali emopoietiche e fattori di crescita

Funding Agency: AIRC Seed grant
Performance Period: 1997-1999
Amount: 30000 €
Role: P.I.

Title of funded proposal: La tirosin fosfatasi recettoriale gamma nel sistema emopoietico normale e nelle neoplasie emolinfopoietiche

Funding Agency: Fondazione Cariverona
Performance Period: 2004-2006
Amount: 52624 €
Role: P.I.

Title of funded proposal: PTPRG as a novel tumor suppressor gene in chronic myeloid leukemia and its clinical implications

Funding Agency: AIRC-IG 4667
Performance Period: 2008-2011
Amount: 150.000 €
Role: P.I.

Title of funded proposal: Effects of azithromycin (AZM) on Pseudomonas-induced chronic lung inflammation in cystic fibrosis

Funding Agency: Italian Cystic Fibrosis Research Foundation (FFC#15/2008)
Performance Period: 2008-2010
Amount: 55000 €
Role: Partner

Title of funded proposal: Functional evaluation of CFTR in blood leukocytes in human subjects as a new tool for diagnostic and clinical research applications

Funding Agency: Italian Cystic Fibrosis Research Foundation (FFC #5/2009)
Performance Period: 2009-2011
Amount: 45000 €
Role: P.I.

Title of funded proposal: Novel biomarkers for evaluation of efficacy of new therapies in cystic fibrosis

Funding Agency: Italian Cystic Fibrosis Research Foundation (FFC #6/2010)
Performance Period: 2010-2012
Amount: 55000 €
Role: Partner

Title of funded proposal: CFTR activity and expression in monocytes of CF patients: possible tools for diagnosis and drug development

Funding Agency: Mucoviscidose : ABCF (France)
Performance Period: 2011
Amount: 30.000 €
Role: Partner

Title of funded proposal: Development of new antibodies for diagnostic application in chronic myeloid leukemia

Funding Agency: University of Verona-Joint Project
Performance Period: 2009-2011
Amount: 45000 €
Role: P.I.

Title of funded proposal: Testing human monocytes as a new tool for clinical and preclinical research in CF

Sorio, Claudio

Funding Agency: Italian Cystic Fibrosis Research Foundation (FFC #26-2011)
Performance Period: 2011-2013
Amount: 70000 €
Role: P.I.

Title of funded proposal: PTPRG in health and disease

Funding Agency: MIUR-F.U.R.
Performance Period: 2010-2011
Amount: 17000 €
Role: P.I.

Title of funded proposal: Role of Protein Tyrosine Phosphatase Gamma (PTPRG) in the pathogenesis of chronic myeloid leukemia (CML) and its evaluation as a new biomarker of disease

Funding Agency: Qatar National Research Fund: NPRP 4-157-3-052
Performance Period: 2013-2016
Amount: 1.004.915,00 USD
Role: P.I.

Title of funded proposal: Establishment of a semi-automated evaluation of CFTR function in blood cells for clinical applications

Funding Agency: Italian Cystic Fibrosis Research Foundation (FFC #06-2013)
Performance Period: 2013-2014
Amount: 40000 €
Role: P.I.

Title of funded proposal: Testing CFTR repair in cystic fibrosis patients carrying nonsense and channel gating mutations

Funding Agency: Italian Cystic Fibrosis Research Foundation (FFC #29-2015)
Performance Period: 2015-2017
Amount: 50000 €
Role: P.I.

Title of funded proposal: Monitoring tyrosine kinase inhibitors efficacy in chronic myeloid leukemia

Funding Agency: University of Verona-Joint Project
Performance Period: 2016-2018
Amount: 46000 €
Role: P.I.

Title of funded proposal: LeukoPredict

Funding Agency: EU proposal 711286 –SME instrument-phase 1
Performance Period: 2016-2017
Amount: 50000 €
Role: Partner-project proponent

Title of funded proposal: Testing intestinal organoids for the prediction of response to CFTR potentiators and correctors used in clinic

Funding Agency: Italian Cystic Fibrosis Research Foundation (FFC #13/2018)
Performance Period: 2018-2020
Amount: 36000 €
Role: P.I.

Title of funded proposal: Theratyping of Cystic Fibrosis

Funding Agency: Italian Ministry of Research (MIUR): 2022FRSS2H
Performance Period: 2023-2025
Amount: 294866 €
Role: P.I. of local unit

Finanziamenti: Accesso ad infrastrutture di ricerca (su base competitiva)

EU FP7 Transnational Access to Research Infrastructures (TARI)

Sorio, Claudio

European Light Sources Activities (ELISA) EC contract N. 226716

Elettra Synchrotron Trieste

2009 - 2010

Experiment 2008232. Detection of drug-induced signatures in normal and in tumor cells by Fourier Transform InfraRed Microspectroscopy (FTIRM).

Experiment 20095114. Fourier Transform InfraRed microscopic analysis of single leukaemic cell.

Role: Partner.

EU FP7 Transnational Access to Research Infrastructures (TARI)

European Light Sources Activities (ELISA) EC contract N. 226716

DLS Diamond Light Source UK

2010 - 2011

Experiment SM 4333-1. Detecting drug effects by Fourier Transform InfraRed microspectroscopy (microFT-IR) on single cells.

Experiment SM6675-1. Testing drug resistance/sensitivity in cancer cell lines by Fourier Transform InfraRed microspectroscopy (microFTIR) and unsupervised pattern recognition.

Role: partner

Period: 06/07/2013 to 31/12/2013

Proposal 20130055 - Type: Standard

SMIS beamline, SOLEIL Synchrotron, Paris, France

Title: Signatures of protein tyrosine phosphatase activity in individual K562 leukocytes analyzed with SR microFTIR and Raman spectroscopy.

Role: partner

EU FP7 Transnational Access to Research Infrastructures (TARI)

European Light Sources Activities (ELISA)

DLS Diamond Light Source UK Beamline: B22: 2012-2013

Experiment SM8087. MicroFTIR analysis of leukemic blast cell models with variable resistance to tyrosine kinase inhibitors.

Role: P.I.

EU FP7 Transnational Access to Research Infrastructures (TARI)

CALIPSO (Coordinated Access to Lightsources to Promote Standards and Optimization)

DLS Diamond Light Source UK Beamline: B22: 2013-2014

Proposal Ref: SM9055

Title: Studying colo-rectal cancer microenvironment by SR infrared spectromicroscopy.

Role: P.I.

EU FP7 Transnational Access to Research Infrastructures (TARI)

CALIPSO (Coordinated Access to Lightsources to Promote Standards and Optimization)

DLS Diamond Light Source UK Beamline: B22: 2013-2014

Proposal Ref: SM9056

Title: Revealing drugs targeting basic defects in cystic fibrosis by SR FTIR microspectroscopy.

Role: partner

EU FP7 Transnational Access to Research Infrastructures (TARI)

CALIPSO (Coordinated Access to Lightsources to Promote Standards and Optimization)

DLS Diamond Light Source UK Beamline: B22: 2013-2014

Proposal Ref: SM9461

Title: Testing CFTR corrector drugs in cystic fibrosis blood monocytes by SR microFTIR.

Role: partner

EU FP7 Transnational Access to Research Infrastructures (TARI)

CALIPSO (Coordinated Access to Lightsources to Promote Standards and Optimization)

DLS Diamond Light Source UK Beamline: B22: 2013-2014

Proposal Ref: SM9460

Title: Molecular characterization of tumour stroma in human colorectal cancer by IR microprobe.

Role: P.I.

Research Support (Peer-reviewed, non competitive)

Sorio, Claudio

Title of funded proposal: Identificazione dei meccanismi molecolari che regolano la differenziazione di cellule leucemiche da parte di agenti chemioterapici e PTPRG tramite l'analisi del proteoma

Funding Agency: Consorzio Studi Universitari-1815/3

Performance Period: 2001-2002

Amount: 7750 €

Role: P.I.

Title of funded proposal: Identificazione dei meccanismi molecolari che regolano la differenziazione di cellule leucemiche da parte di agenti chemioterapici e PTPRG tramite l'analisi del proteoma

Funding Agency: Consorzio Studi Universitari-277/3

Performance Period: 2002-2003

Amount: 18075 €

Role: P.I.

Title of funded proposal: Support for clinical trials in cystic fibrosis

Funding Agency: Clinical Research Center-Verona

Performance period: 2015-2016

Amount: 120000 €

Role: P.I.

Title of funded proposal: Effects of PDE4 inhibitors on CFTR expression and function in in vitro models of cystic fibrosis and COPD

Funding Agency: Chiesi farmaceutici (ODA 45000 63815)

Performance period: 2015-2017

Amount: 80703 €

Role: P.I.

Title of funded proposal: PARTICIPATION IN THE CLINICAL TRIAL NETWORK (ASSAEL08A0)

Funding Agency: Cystic Fibrosis Foundation Therapeutics, Inc. (USA)

Performance period: 2012-2022

Amount: 600000 USD

Role: Partner

Title of funded proposal: Evaluation of the effect of PTC-124 on human intestinal organoids and monocytes

Funding Agency: PTC therapeutics-USA

Performance Period: 2016-2018

Amount: 128000 €

Role: P.I.

Title of funded proposal: Effects of PDE4 inhibitors on CFTR expression and function in in vitro models of cystic fibrosis

Funding Agency: Chiesi farmaceutici (RDA 10188791)

Performance period: 2018-2020

Amount: 99308 €

Role: P.I.

Title of funded proposal: "Applicazione di sistemi Nano-Electrode Ensemble (NEA) al monitoraggio dell'attività della chinasi chimerica ABL e dell'inibizione operata dai farmaci inibitori della tirosina chinasi nel trattamento della Leucemia Mieloide Cronica (CML). Studio e sperimentazione di sistemi basati su biosensore per la rilevazione in siero di biomarcatori

Funding Agency: AB Analitica

Performance period: 2018-2019

Amount: 30000 €

Role: P.I.

Title of funded proposal: Effects of PDE4 inhibitors on CFTR expression and function in in vitro models of cystic fibrosis

Funding Agency: Chiesi farmaceutici

Performance period: 2023-2024

Amount: 50754 €

Role: P.I.

D.

Editorial Board Member: World Journal of Gastrointestinal Oncology (WJGO), American Journal of Cancer Research, Science Letters, Biomolecules (MDPI), Cancers (MDPI).

Section Editor: Biomolecules (Cellular biochemistry)

Deputy Editor-in-Chief: World Journal of Hematology.

Co-Editor in chief: Advances in Redox Research (Elsevier)

Review Editor for Frontiers Pharmacology

E. Conferenze su invito/attività correlate:

- 1) Invited speaker satellite meetings: Biomarkers to personalize treatment of the basic defect and to monitor early response: XIII CONVENTION OF FFC INVESTIGATORS IN CYSTIC FIBROSIS: in sessions "Biomarkers to personalize treatment of the basic defect and to monitor early response" and "Biomarkers as potential predictors of treatment effectiveness before therapy in individual patients": Poiano Hotel Resort Garda-Verona 26-28 november 2015
- 2) Invited speaker: "The host's and pathogen's sides in cystic fibrosis: some views in a open field" 2016 ECFS Basic Science Conference, Pisa, Italy (March 30 - April 2, 2016).
- 3) Chairman: Italian Society of Cancerology, 58th national congress, 2016, Verona, Italy: Cancer genetics, epigenetics and control of gene expression session
- 4) Chairman: XIV CONVENTION OF FFC INVESTIGATORS IN CYSTIC FIBROSIS: Poiano Hotel Resort Garda-Verona 24-26 november 2016
- 5) Invited speaker: HUMAN ANTIBODIES & HYBRIDOMAS - HAH 2016 9-11 November 2016, Hilton Hotel, Belfast, Northern Ireland, UK
- 6) Invited speaker: SIGO 2017 (Shanghai International Gastrointestinal Oncology Symposium)
- 7) Member of the organizing committee of the 13th International Conference on Laboratory Medicine & Pathology March 05-07, 2018 Berlin, Germany
- 8) Invited speaker: 17th Scientific Meeting: Organoids as models of disease and treatment in CF. September 21th+22nd 2017, Schloss Waldhausen, Mainz-Germany
- 9) Chairman XV CONVENTION OF FFC INVESTIGATORS IN CYSTIC FIBROSIS: 26-28 October 2017 Camera di Commercio Verona, Congress Center Corso Porta Nuova, 96
- 10) Organizer: AICC International WORKSHOP ON ORGANOID CULTURES, Verona, March 8, 2018
- 11) Invited speaker, XIV MEETING NAZIONALE DELLA SOCIETA' ITALIANA PER LO STUDIO DELLA FIBROSI CISTICA, May 4-5, 2018 Roma, Italy
- 12) Invited speaker, XV MEETING NAZIONALE DELLA SOCIETA' ITALIANA PER LO STUDIO DELLA FIBROSI CISTICA, May 4-5, 2019 Rimini, Italy
- 13) Invited speaker, XLIII MEETING NAZIONALE DELLA SOCIETA' ITALIANA PER LO STUDIO DEL PANCREAS, September 19-21, 2019 Verona, Italy
- 14) Invited speaker, XXVII CONGRESSO ITALIANO DELLA FIBROSI CISTICA, XVII Congresso Nazionale della Società Italiana per lo studio della Fibrosi Cistica October 20-23, 2021 Napoli, Italy
- 15) Invited speaker, XVII MEETING NAZIONALE DELLA SOCIETA' ITALIANA PER LO STUDIO DELLA FIBROSI CISTICA, May 6-7, 2022 Parma, Italy
- 16) Invited speaker, 21th Scientific Meeting Innovative Therapies in CF, 29th-30th September 2022 Schloss Montabaur, Montabaur (Germany)
- 17) Invited speaker, North America Cystic Fibrosis Conference (NACFC 2022), 2nd-5th November 2022, Philadelphia (USA)
- 18) Invited speaker 20th Annual Meeting, Montpellier, France 9-11 February 2023 European Cystic Fibrosis Society Diagnostic Network Working Group

F. Premi:

Young investigator award for the study: A "Shotgun" Proteomic Approach Identify Versican and MAC25/Angiomodulin as Novel Molecules Released by Pancreatic Cancer Cells: A Preliminary Characterization Mafficini A., Scarpa A., Mauri P., Bassi C., Mina M., Bonora A., Pederzoli P., Sorio C. AISP - 28th National Congress. Verona (Italy). October 28-30, 2004. Published in JOP. Journal of the Pancreas – <http://www.joplink.net> – Vol. 5, No. 5 Supplement – September 2004. [ISSN 1590-8577]

Investigator award for the study: "Protein tyrosine phosphatase receptor type gamma (PTPRG) is a functional tumor suppressor gene specifically down-regulated in chronic myeloid leukemia (CML) " by Moratti E.; Della Peruta M.; Vezzalani M.; Pintani D.; Mafficini A.; Tecchio C.; Monne M.; Sorio C. XXX international congress (SIP-ASIP), University of Salerno & the Grand Hotel Salerno October 14-17, 2010 published in Am J Pathol. 2010 Oct;177 Suppl:S1-35.

Sorio, Claudio

Best poster award for the study: STUDIO DI MECCANISMI ANTI-INFIAMMATORI DELL' AZITROMICINA: DALL' EPITELIO BRONCHIALE UMANO CON FIBROSI CISTICA ALL' IMAGING DELL'ATTIVAZIONE DI NF-KB IN VIVO. F. Stellari, C. Cigana, G. Bergamini, C. Sorio, F. Ruscitti, G. Villetti, B. Assael and P. Melotti. XIX Congresso Italiano della Fibrosi Cistica IX Congresso Nazionale della Società Italiana per lo Studio della Fibrosi Cistica (SIFC), Palermo 13-16 November 2013, Hotel Città del Mare, Terrasini (PA)

"Azithromycin effect on lung inflammation induced by pseudomonas aeruginosa released proteases as shown by in vivo imaging in il-8 transiently transgenized mice" Gabriella Bergamini, Fabio Stellari, Angela Sandri, Francesca Ruscitti, Gino Villetti, Claudio Sorio, Paola Melotti, Baroukh Maurice Assael, Maria M Lleo
Selected among "best 10 posters" at the North American Cystic Fibrosis Conference, Atlanta, USA 9-11 October 2014.

Luisa Tomasello, Marzia Vezzalini, Iaria Pergher, Elisa Gardiman, Massimiliano Bonifacio, Mauro Krampera, Mohamed Yassin, Nader Al-Dewik and Claudio Sorio
Regulative Loop between β -Catenin and Protein Tyrosine Phosphatase Receptor Type γ (PTPRG) in Chronic Myeloid Leukemia
18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, September 15 - September 18, 2016 – Houston, TX ORAL PRESENTATION- TRAVEL GRANT . 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy September 15-18, 2016 – Houston, TX, USA

Luisa Tomasello, Marzia Vezzalini, Iaria Pergher, Elisa Gardiman, Massimiliano Bonifacio, Mauro Krampera, Mohamed Yassin, Nader Al-Dewik and Claudio Sorio
Regulative Loop between β -Catenin and Protein Tyrosine Phosphatase Receptor Type γ (PTPRG) in Chronic Myeloid Leukemia
XIV Congresso Nazionale SIES 2016 Rimini, October 19-21 2016 ORAL PRESENTATION- TRAVEL GRANT

G.

Deputy Editor-in-Chief: World Journal of Hematology.

Co-Editor in chief: Advances in Redox Research (Elsevier)

Associate editor for Frontiers in Oncology (Hematologic Malignancies).

Associate editor for Frontiers in Molecular Biosciences (Molecular Diagnostics and Therapeutics).

Review Editor for Frontiers Pharmacology (Experimental Pharmacology and Drug Discovery)

Editorial Board Member: World Journal of Gastrointestinal Oncology (WJGO), American Journal of Cancer Research, Science Letters , Biomolecules (MDPI), Cancers (MDPI), Kinase and Phosphatases (MDPI).

Revisore per: Cancer Research, Clinical Endocrinology, Journal of Leukocyte Biology, Proteomics, Journal of Translational Medicine, Journal of Pathology, Clinical Biochemistry, Molecular Cancer, BMC Cancer, Critical Reviews in analytical chemistry, Current Signal Transduction, European Journal of Pediatrics, International Journal of Biochemistry Research & Review, PlosOne, World Journal of Gastrointestinal Oncology, Oncotarget, BioMed Research International, Frontiers Pharmacology, Journal of Clinical Investigation, Thorax, Pediatric Research, iScience, JBS, Blood

H. International and National bodies:

Advisor: Pancreatic Cancer UK agency (www.pancreaticcancer.org.uk), Prostate Action UK (www.prostateaction.org.uk); King Badouin Foundation, Belgium,

Member: European Cystic Fibrosis Society (ECFS) Cystic Fibrosis Molecular & Cell Biology and Physiology Basic Science Working Group (ECFS Basic Science WG)

I: Reviewer di programmi di ricerca nazionali ed internazionali:

- 1) Italy (SIR: Scientific Independence of Young Researchers),
- 2) Fundamental Research Projects (FARB)
- 3) University of Bologna (Italy),
- 4) France Ministry of University, France
- 5) Polish National Science Centre (Narodowe Centrum Nauki - NCN; <http://www.ncn.gov.pl>)
- 6) External Reviewer for Cystic Fibrosis Canada (www.cysticfibrosis.ca)
- 7) Pancreatic Cancer UK (PCUK)
- 8) Cancer Research UK

L. Attività didattica e di consulenza :

Partecipa a consigli di:

Corso di dottorato di ricerca in "inflammation, Immunity and Cancer"

Corso di dottorato di ricerca "Molecular and cellular biology and pathology "

Corso di specializzazione in "Oncologia Medica" (1999-2013)

CdL fisioterapia

CdL infermieristica

Dipartimento di Medicina

Attività:

1. Professore supplente (patologia ed oncologia) alla facoltà di scienze dell' Università of Verona (2006)
2. Docente di "Patologia Generale Oncologica" per il I e II anno della scuola di specializzazione in Oncologia Medica dell'Università di Verona (1999-2013);
3. Coordinatore (dall'a.a. 2010/11) del corso magistrale "Fisiopatologia applicata all'infermieristica" (9 crediti) ain Verona and Vicenza: attività didattica a partire dal 1999.
4. Coordinatore (dall'a.a. 2007/08) del corso magistrale "Patologia" nel CdL in Fisioterapia (4 crediti) di Verona e Vicenza, attività didattica a partire dal 1999
5. Fa parte del corpo docente del Dottorato di Ricerca in Biologia e Patologia Molecolare e Cellulare presso l'Università di Verona (1999-2005), successivamente della Scuola per il Dottorato in Scienze Biomediche Traslazionali (2006-presente).
6. Scuola di Medicina e Chirurgia: lezioni nel corso di patologia generale
7. Scuola di Medicina e Chirurgia: progetto TANDEM (16 ore di lezione frontale/anno accademico):
<http://www.univr.it/main?ent=servizioaol&idDest=3&sServ=72&serv=71&lang=en>
8. Nominato Visiting Professor all' Università del Minnesota, Department of Biochemistry Molecular Biology and Biophysics (2014)
9. Consulenza presso il National Center for Cancer Care & Research Center (NCCCCRC), Hamad Medical Center (Doha, Qatar)
10. Corso di patologia alla Università internazionale "LUISS Guido Carli", Roma, Italy (2014-2017; 2019)
11. Teaching at the Medical postgraduate specialization program
12. Membro del comitato di valutazione della dissertazione della tesi di dottorato: **HER2 modifies acid-base regulation and sensing to facilitate breast cancer development** (The Graduate School, Health, Aarhus University, DK). March 3, 2023
13. Presidente, assessment committee of the PhD dissertation of the 39th PhD cycle "Immunity , infection and cancer" October 6th, 2023
14. componente Collegio dei Docenti del Dottorato in Infiammazione, Immunità e Cancro - Dipartimento Medicina
15. componente Collegio Didattico del Corso di Laurea in Fisioterapia - Medicina e Chirurgia
16. componente Collegio didattico del Corso di Laurea in Medicina e Chirurgia - Medicina e Chirurgia
17. componente Collegio Didattico unificato di Fisioterapia e Scienze Riabilitative delle Professioni Sanitarie - Medicina e Chirurgia
18. componente Collegio Didattico unificato di Infermieristica e Scienze Infermieristiche ed Ostetriche - Medicina e Chirurgia
19. componente Commissione Internazionalizzazione (CLM a ciclo unico in Farmacia) - Collegio Didattico del Corso di Laurea Magistrale a ciclo unico in Farmacia - Medicina e Chirurgia
20. associato Consiglio del Dipartimento di Medicina - Dipartimento Medicina
21. Referenti di anno di corso/Tutor didattici - Collegio Didattico del Corso di Laurea Magistrale a ciclo unico in Farmacia - Medicina e Chirurgia

M: Supervisore e Correlatore di Tesi di laurea specialistica (CTF, medicina), di tecnici di laboratorio (3), di infermieristica (1), di specializzazione (Anatomia Patologica): 1, di dottorato di ricerca (7) . Sette ricercatori a contratto hanno frequentato il laboratorio (attualmente frequentato da 1 studente di dottorato, 2 ricercatori a contratto and 1 tecnico di laboratorio).

N: Membro delle seguenti società scientifiche: SIP, SIICA, SIC, EACR, ASH, EHA, ECFS, SIFC

Sito istituzionale:

<http://www.dpd.univr.it/?ent=persona&id=1181&lang=en>;

Verona, 09/09/2024

Claudio Sorio